8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report

(Date of earliest event reported):

October 25, 2022

NEXTGEN HEALTHCARE, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-12537	95-2888568
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
Not Applicable(1)		Not Applicable(1)
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: Not Applicable⁽¹⁾

3525 Piedmont Rd., NE, Building 6, Suite 700, Atlanta, GA 30305

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock (Par Value $0.01)	NXGN	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

(1) NextGen Healthcare, Inc. is a remote-first company and no longer maintains its principal executive office. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and Securities Exchange Act of 1934, as amended, stockholder communications required to be sent to our principal executive offices should be directed to the email address set forth in our proxy materials and/or identified on our investor relations website.

Item 2.02   Results of Operations and Financial Condition.

On October 25, 2022, NextGen Healthcare, Inc. (the “Company”) issued a press release announcing its financial performance for the period ended September 30, 2022. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1 104	Press Release dated October 25, 2022 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 25, 2022	NEXTGEN HEALTHCARE, INC.
	By:	/s/ James R. Arnold, Jr.
		James R. Arnold, Jr.
		Chief Financial Officer

EX-99.1

Exhibit 99.1

 

NextGen Healthcare Reports Fiscal 2023 Second Quarter Results

Raises Fiscal 2023 Financial Guidance

REMOTE-FIRST COMPANY/NEW YORK – October 25, 2022 – NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced its operating results for the fiscal second quarter ended September 30, 2022.  

Fiscal 2023 Second Quarter Highlights

• Total revenue was $159.4 million compared to $149.3 million for the same period a year ago, an increase of 7%.

• Recurring revenue was $143.5 million compared to $135.6 million for the same period a year ago, an increase of 6%.

• Non-recurring revenue was $15.9 million compared to $13.7 million for the same period a year ago, an increase of 17%.

• Bookings, which reflects annual contract value, was $37.4 million and included several deals greater than $1.0 million.

• Fully diluted net income per share was $0.20 compared to a net loss of $0.10 for the same period a year ago.

• On a non-GAAP basis, fully diluted earnings per share was $0.25 compared to $0.29 for the same period a year ago.  

• Board authorized new share repurchase program under which the Company may repurchase up to an additional $100 million of its outstanding shares of common stock through March 2025.

“We are pleased with the team’s consistent performance and solid execution which has resulted in exceeding our initial growth targets and increasing financial guidance for the remainder of the year,” said David Sides, President and Chief Executive Officer of NextGen Healthcare. “Notably, we’ve seen expanded adoption of our integrated solution and are continuing to develop next generation improvements that will further enhance the patient and provider experience.”

Based on the first half performance and updated view of the business, our revised guidance for fiscal 2023 is now as follows:

• Revenue is expected between $630 million and $640 million, from between $621 million and $633 million.

• Adjusted EBITDA is expected between $110 million and $115 million, from between $109 million and $114 million.

• Non-GAAP earnings per share is expected between $0.93 and $0.99, from between $0.92 and $0.98.

Conference Call Information

NextGen Healthcare will host a conference call today at 5:00 p.m. EST to discuss operating results from its fiscal 2023 second quarter. Shareholders and interested participants may listen to a live broadcast of the call by dialing 800-343-5172 or 203-518-9848 for international callers and referencing participant code NXGNQ223 approximately 15 minutes prior to the call. A recording of the live webcast will be available on investor.nextgen.com after the call. It will be archived for 90 days.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding our fiscal year 2023 outlook, financial and operating results, strategic priorities, growth initiatives and expected capital expenditures. These forward-looking statements are based on the current beliefs, expectations, and assumptions of the Company's management relating to the future (including, without limitation, statements concerning revenue, net income, and earnings per share). The words “positioned,” “proposed,” “potential,” “project,” “expect,” “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “estimate, “strategy,” “expectations,” “future,” “likely,” “may,” “should,” “will,” variations thereof or similar expressions are intended to identify such forward-looking statements.  

Risks and uncertainties exist that may cause the results to differ materially from those set forth in these forward-looking statements, including but not limited to: changes in laws and regulations applicable to our business; changes in market conditions and receptivity to our services and offerings; strategic actions, including acquisitions and dispositions and our success in integrating acquired businesses; our ability to maintain and expand our business with existing clients or effectively transition clients to newer products; our ability to attract new partners and successfully capture new opportunities; our ability to develop and grow partner relationships; our ability to attract and retain key employees; our ability to anticipate or respond quickly to market changes, execute our strategy and manage growth; the impact of litigation and governmental and regulatory agency investigations; the impact of governmental and regulatory agency investigations; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; the impact of the COVID-19 pandemic on our operations and demand for our services; impact of breaches or failures of the Company’s information security measures or unauthorized access to a customer’s data; disruptions caused by acquisitions of companies, products, or technologies; and general economic conditions.  Additional discussion of these and other risks, uncertainties and factors affecting our business is contained in our filings with the SEC, including our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q.

A significant portion of the Company's quarterly sales of software product licenses and computer hardware is concluded in the last month of a fiscal quarter, generally with a concentration of such revenues earned in the final ten business days of that month. Due to these and other factors, the Company's revenues and operating results are very difficult to forecast. A major portion of the Company's costs and expenses, such as personnel and facilities, are of a fixed nature and, accordingly, a shortfall or decline in quarterly and/or annual revenues typically results in lower profitability or losses. As a result, comparison of the Company's period-to-period financial performance is not necessarily meaningful and should not be relied upon as an indicator of future performance. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

USE OF NON-GAAP FINANCIAL MEASURES

This news release contains certain non-GAAP (Generally Accepted Accounting Principles) financial measures, which are provided only as supplemental information. Investors should consider these non-GAAP financial measures only in conjunction with the comparable GAAP financial measures. These non-GAAP measures are not in accordance with or a substitute for U.S. GAAP. Pursuant to the requirements of Regulation G, the Company has provided a reconciliation of non-GAAP financial measures to the most directly comparable financial measure in the accompanying financial tables. Other companies may calculate non-GAAP measures differently than NextGen Healthcare, Inc., which limits comparability between companies. The Company believes that its presentation of non-GAAP diluted earnings per share provides useful supplemental information to investors and management regarding the Company's financial condition and results. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP.

The Company calculates non-GAAP diluted earnings per share by excluding net acquisition costs, amortization of acquired intangible assets, amortization of deferred debt issuance costs, gain on disposition of Commercial Dental assets, impairment of assets, restructuring costs, shareholder disputes and related costs, net of insurance, which include net securities litigation defense, proxy contest, and related costs, share-based compensation, and other non-run-rate expenses from GAAP income before provision for income taxes.

The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each quarter of fiscal year 2023 is 20.0%. The determination of this rate is based on the consideration of both historic and projected financial results. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occur that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

The Company calculates free cash flow as total net cash provided by operating activities, net of cash used for the additions of capitalized software costs and equipment and improvements. The Company calculates net debt as line of credit less cash and cash equivalents. The Company calculates non-GAAP adjusted EBITDA by excluding net acquisition costs, amortization of acquired intangible assets, impairment of assets, restructuring costs, shareholder disputes and related costs, net of insurance, which include net securities litigation defense, proxy contest, and related costs, share-based compensation, and other non-run-rate expenses from GAAP income from operations and then adding back amortization of capitalized software costs and depreciation as presented within the condensed consolidated statements of cash flows. Non-GAAP adjusted EBITDA margin is calculated as non-GAAP adjusted EBITDA divided by total revenues. The Company calculates Rule of 40 as annual revenue growth rate plus non-GAAP adjusted EBITDA margin.

The Company’s future period guidance in this release includes adjustments for items not indicative of the Company’s core operations. Such adjustments are generally expected to be of a nature similar to those

adjustments applied to the Company’s historic GAAP financial results in the determination of the Company’s non-GAAP diluted earnings per share. Such adjustments, however, may be affected by changes in ongoing assumptions and judgments as to the items that are excluded in the calculation of non-GAAP adjusted net income and adjusted diluted earnings per share, as described in this release. The exact amount and probable significance of these adjustments, including net acquisition costs, impairment of assets, restructuring costs, shareholder disputes and related costs, which include net securities litigation defense, proxy contest, and related costs, and other non-run-rate expenses, are not currently determinable without unreasonable efforts, but may be significant. These items cannot be reliably quantified or forecasted due to the combination of their historic and expected variability. It is therefore not practicable to reconcile this non-GAAP guidance to the most comparable GAAP measures.

About NextGen Healthcare, Inc.

NextGen Healthcare, Inc. (Nasdaq: NXGN) is a leading provider of innovative healthcare technology solutions. We are reimagining ambulatory healthcare with award-winning solutions that enable high-performing practices to create healthier communities. We partner with medical, behavioral and dental providers in their journey toward whole person health and value-based care. Our highly integrated, intelligent and interoperable solutions go beyond EHR and Practice Management to increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a quest to achieve better healthcare outcomes for all. Learn more at nextgen.com, and follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Media Relations Contact

Tami Andrade

(949) 237-6083

tandrade@nextgen.com

Investor Relations Contact

James Hammerschmidt

(949) 237-6112

jhammerschmidt@nextgen.com

NEXTGEN HEALTHCARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(In thousands, except per share data)

(Unaudited)

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Revenues:
Recurring	$	143,503		$	135,609		$	283,262		$	267,990
Software, hardware, and other non-recurring		15,940			13,677			29,483			27,380
Total revenues		159,443			149,286			312,745			295,370
Cost of revenue:
Recurring		65,039			57,119			127,283			114,279
Software, hardware, and other non-recurring		10,797			7,610			21,473			15,107
Amortization of capitalized software costs and acquired intangible assets		6,744			7,969			13,878			16,053
Total cost of revenue		82,580			72,698			162,634			145,439
Gross profit		76,863			76,588			150,111			149,931
Operating expenses:
Selling, general and administrative		44,886			63,891			93,920			112,377
Research and development costs, net		20,857			18,518			42,652			37,839
Amortization of acquired intangible assets		705			881			1,410			1,762
Impairment of assets		805			1,195			1,329			1,577
Restructuring costs		321			—			321			539
Total operating expenses		67,574			84,485			139,632			154,094
Income (loss) from operations		9,289			(7,897	)		10,479			(4,163	)
Interest income		74			17			120			29
Interest expense		(325	)		(320	)		(655	)		(637	)
Other income (expense), net		10,292			(12	)		10,287			(34	)
Income (loss) before provision for (benefit of) income taxes		19,330			(8,212	)		20,231			(4,805	)
Provision for (benefit of) income taxes		5,707			(1,441	)		5,460			(882	)
Net income (loss)	$	13,623		$	(6,771	)	$	14,771		$	(3,923	)
Net income (loss) per share:
Basic	$	0.20		$	(0.10	)	$	0.22		$	(0.06	)
Diluted	$	0.20		$	(0.10	)	$	0.22		$	(0.06	)
Weighted-average shares outstanding:
Basic		67,806			67,406			67,698			67,291
Diluted		68,422			67,406			68,353			67,291

NEXTGEN HEALTHCARE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

(Unaudited)

	September 30, 2022			March 31, 2022
ASSETS
Current assets:
Cash and cash equivalents	$	70,728		$	59,829
Restricted cash and cash equivalents		7,580			6,918
Accounts receivable, net		76,948			76,057
Contract assets		25,474			25,157
Income taxes receivable		3,052			6,507
Prepaid expenses and other current assets		34,363			37,102
Total current assets		218,145			211,570
Equipment and improvements, net		7,398			9,120
Capitalized software costs, net		49,791			43,958
Operating lease assets		5,197			11,316
Deferred income taxes, net		19,128			19,259
Contract assets, net of current		1,595			1,910
Intangibles, net		19,739			24,303
Goodwill		267,212			267,212
Other assets		38,933			39,026
Total assets	$	627,138		$	627,674
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	12,414		$	9,125
Contract liabilities		62,498			61,280
Accrued compensation and related benefits		28,113			48,736
Income taxes payable		172			99
Operating lease liabilities		7,095			8,089
Other current liabilities		58,320			53,533
Total current liabilities		168,612			180,862
Deferred compensation		6,981			7,230
Operating lease liabilities, net of current		5,147			11,934
Other noncurrent liabilities		4,556			4,570
Total liabilities		185,296			204,596
Commitments and contingencies
Shareholders' equity:
Common stock, $0.01 par value; authorized 100,000 shares; 70,351 shares and 69,245 shares issued at September 30, 2022 and March 31, 2022, respectively; 67,605 shares and 67,075 shares outstanding at September 30, 2022 and March 31, 2022, respectively		704			692
Treasury stock, at cost, 2,746 shares and 2,170 shares at September 30, 2022 and March 31, 2022, respectively		(45,752	)		(35,874	)
Additional paid-in capital		343,809			329,917
Accumulated other comprehensive loss		(1,942	)		(1,909	)
Retained earnings		145,023			130,252
Total shareholders' equity		441,842			423,078
Total liabilities and shareholders' equity	$	627,138		$	627,674

NEXTGEN HEALTHCARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Cash flows from operating activities:
Net income (loss)	$	13,623		$	(6,771	)	$	14,771		$	(3,923	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Amortization of capitalized software costs		5,371			5,751			10,725			11,617
Amortization of debt issuance costs		127			127			254			254
Amortization of other intangibles		2,078			3,099			4,564			6,198
Deferred income taxes		—			1			—			29
Depreciation		1,354			1,673			2,646			3,781
Excess tax deficiency (benefit) from share-based compensation		(23	)		816			(434	)		640
Gain on disposition of Commercial Dental assets		(10,296	)		—			(10,296	)		—
Impairment of assets		805			1,195			1,329			1,577
Loss on disposal of equipment and improvements		33			39			74			77
Loss on foreign currency exchange rates		1			—			7			—
Non-cash operating lease costs		768			1,459			1,682			3,087
Provision for bad debts		359			40			600			679
Share-based compensation		8,687			5,223			17,453			11,635
Changes in assets and liabilities:
Accounts receivable		(63	)		1,467			(1,527	)		4,874
Contract assets		124			(136	)		(2	)		(1,055	)
Accounts payable		(2,676	)		5,442			3,153			1,108
Contract liabilities		(75	)		1,225			1,739			643
Accrued compensation and related benefits		2,246			5,643			(20,422	)		(16,321	)
Income taxes		4,125			(9,788	)		3,934			(9,324	)
Deferred compensation		(200	)		(88	)		(249	)		655
Operating lease liabilities		(2,012	)		(2,684	)		(4,097	)		(5,360	)
Other assets and liabilities		14,085			6,433			7,892			9,608
Net cash provided by operating activities		38,441			20,166			33,796			20,479
Cash flows from investing activities:
Additions to capitalized software costs		(9,418	)		(6,175	)		(18,416	)		(11,713	)
Additions to equipment and improvements		(971	)		(683	)		(1,426	)		(1,685	)
Proceeds from disposition of Commercial Dental assets		11,253			—			11,253			—
Net cash provided by (used in) investing activities		864			(6,858	)		(8,589	)		(13,398	)
Cash flows from financing activities:
Proceeds from issuance of shares under employee plans		507			438			2,575			1,109
Repurchase of common stock		(7,373	)		—			(9,878	)		—
Payments for taxes related to net share settlement of equity awards		(2,456	)		(2,232	)		(6,124	)		(5,201	)
Net cash used in financing activities		(9,322	)		(1,794	)		(13,427	)		(4,092	)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash		(90	)		—			(219	)		—
Net increase in cash, cash equivalents, and restricted cash		29,893			11,514			11,561			2,989
Cash, cash equivalents, and restricted cash at beginning of period		48,415			70,050			66,747			78,575
Cash, cash equivalents, and restricted cash at end of period	$	78,308		$	81,564		$	78,308		$	81,564

NEXTGEN HEALTHCARE, INC.

SUPPLEMENTAL FINANCIAL INFORMATION

(In thousands)

The following table presents our revenues disaggregated by our major revenue categories and by occurrence:

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Recurring revenues:
Subscription services	$	43,416		$	41,139		$	86,175		$	79,423
Support and maintenance		38,150			39,004			77,288			77,490
Managed services		31,055			28,207			61,700			56,115
Transactional and data services		30,882			27,259			58,099			54,962
Total recurring revenues		143,503			135,609			283,262			267,990
Software, hardware, and other non-recurring revenues:
Software license and hardware		7,916			8,068			14,115			15,282
Other non-recurring services		8,024			5,609			15,368			12,098
Total software, hardware and other non-recurring revenues		15,940			13,677			29,483			27,380
Total revenues	$	159,443		$	149,286		$	312,745		$	295,370
Recurring revenues as a percentage of total revenues		90.0	%		90.8	%		90.6	%		90.7	%

NEXTGEN HEALTHCARE, INC.

NON-GAAP FINANCIAL MEASURES

(In thousands, except per share data)

RECONCILIATION OF NON-GAAP DILUTED EARNINGS PER SHARE

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Income (loss) before provision for income taxes - GAAP	$	19,330		$	(8,212	)	$	20,231		$	(4,805	)
Non-GAAP adjustments:
Acquisition costs, net		225			—			225			—
Amortization of acquired intangible assets		2,078			3,100			4,564			6,199
Amortization of deferred debt issuance costs		127			127			254			254
Gain on disposition of Commercial Dental assets		(10,296	)		—			(10,296	)		—
Impairment of assets		805			1,195			1,329			1,577
Restructuring costs		321			—			321			539
Shareholder disputes and related costs, net of insurance		224			22,134			345			26,992
Share-based compensation		8,687			5,223			17,453			11,635
Other non-run-rate expenses*		205			1,309			612			4,028
Total adjustments to GAAP income before provision for income taxes:		2,376			33,088			14,807			51,224
Income before provision for income taxes - Non-GAAP		21,706			24,876			35,038			46,419
Provision for income taxes		4,342			4,975			7,008			9,284
Net income - Non-GAAP	$	17,364		$	19,901		$	28,030		$	37,135
Diluted net income per share - Non-GAAP	$	0.25		$	0.29		$	0.41		$	0.55
Weighted-average shares outstanding (diluted):		68,422			67,699			68,353			67,734
* Other non-run-rate expenses for the three months ended September 30, 2022 consist of $205 excess lease-related expense for vacated facilities. Other non-run-rate expenses for the three months ended September 30, 2021 consist primarily of $353 excess lease-related expense for vacated facilities, lease termination costs, and other costs, $458 of executive transition costs, and $498 of incremental costs and penalties primarily due to the cancellation of certain events directly associated with the COVID-19 pandemic. Other non-run-rate expenses for the six months ended September 30, 2022 consist of $462 excess lease-related expense for vacated facilities and $150 of professional services costs not related to core operations. Other non-run-rate expenses for the six months ended September 30, 2021 consist primarily of $823 excess lease-related expense for vacated facilities, lease termination costs, and other costs, including retention bonuses, related to the restructuring plan, $2,707 of executive transition costs, including severance and other costs related to the departure of the CEO, and $498 of incremental costs and penalties primarily due to the cancellation of certain events directly associated with the COVID-19 pandemic.

RECONCILIATION OF FREE CASH FLOW

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Net cash provided by operating activities	$	38,441		$	20,166		$	33,796		$	20,479
Additions to capitalized software costs		(9,418	)		(6,175	)		(18,416	)		(11,713	)
Additions to equipment and improvements		(971	)		(683	)		(1,426	)		(1,685	)
Free cash flow	$	28,052		$	13,308		$	13,954		$	7,081

NEXTGEN HEALTHCARE, INC.

NON-GAAP FINANCIAL MEASURES

(In thousands)

RECONCILIATION OF ADJUSTED EBITDA

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Income (loss) from operations - GAAP	$	9,289		$	(7,897	)	$	10,479		$	(4,163	)
Non-GAAP adjustments:
Acquisition costs, net		225			—			225			—
Amortization of acquired intangible assets		2,078			3,100			4,564			6,199
Impairment of assets		805			1,195			1,329			1,577
Restructuring costs		321			—			321			539
Shareholder disputes and related costs, net of insurance		224			22,134			345			26,992
Share-based compensation		8,687			5,223			17,453			11,635
Other non-run-rate expenses*		205			1,309			612			4,028
Total adjustments to GAAP income from operations		12,545			32,961			24,849			50,970
Income from operations - Non-GAAP		21,834			25,064			35,328			46,807
Amortization of capitalized software costs		5,371			5,751			10,725			11,617
Depreciation		1,354			1,673			2,646			3,781
Depreciation and Amortization - Non-GAAP		6,725			7,424			13,371			15,398
Adjusted EBITDA - Non-GAAP	$	28,559		$	32,488		$	48,699		$	62,205
Total revenues	$	159,443		$	149,286		$	312,745		$	295,370
Adjusted EBITDA margin - Non-GAAP		17.9	%		21.8	%		15.6	%		21.1	%
* Other non-run-rate expenses for the three months ended September 30, 2022 consist of $205 excess lease-related expense for vacated facilities. Other non-run-rate expenses for the three months ended September 30, 2021 consist primarily of $353 excess lease-related expense for vacated facilities, lease termination costs, and other costs, $458 of executive transition costs, and $498 of incremental costs and penalties primarily due to the cancellation of certain events directly associated with the COVID-19 pandemic. Other non-run-rate expenses for the six months ended September 30, 2022 consist of $462 excess lease-related expense for vacated facilities and $150 of professional services costs not related to core operations. Other non-run-rate expenses for the six months ended September 30, 2021 consist primarily of $823 excess lease-related expense for vacated facilities, lease termination costs, and other costs, including retention bonuses, related to the restructuring plan, $2,707 of executive transition costs, including severance and other costs related to the departure of the CEO, and $498 of incremental costs and penalties primarily due to the cancellation of certain events directly associated with the COVID-19 pandemic.

XML

Document and Entity Information	Oct. 25, 2022
Document Information [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 25, 2022
Entity Registrant Name	NEXTGEN HEALTHCARE, INC.
Entity Central Index Key	0000708818
Entity Emerging Growth Company	false
Entity File Number	001-12537
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	95-2888568
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Document - Document and Entity Information [Line Items]
Security 12b Title	Common Stock (Par Value $0.01)
Trading Symbol	NXGN
Security Exchange Name	NASDAQ
Former Address
Document Information [Line Items]
Entity Address, Address Line One	3525 Piedmont Rd.
Entity Address, Address Line Two	NE
Entity Address, Address Line Three	Building 6, Suite 700
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30305